1 active not recruiting, 1 completed, 1 unknown. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Mendel AI: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Leveraging EA8191 to Assess AI-Augmented EHR Abstraction Chart review - Prostate Cancer | Active not recruiting | University of Pennsylvania | 300 | 2025-04-04 | 2026-06-17 | |
| Assessing the Performance of Artificial Intelligence (AI)-Augmented Electronic Health Record (EHR) Data Abstraction for Clinical Trial Patient Screening Chart review - Cancer | Completed | University of Pennsylvania | 355 | 2023-08-18 | 2025-07-25 | |
| The Potential Protective Role of Venlafaxine Versus Memantine in Paclitaxel Induced Peripheral Neuropathy Venlafaxine, Memantine - Oncology Pain, Chemotherapy-induced Peripheral Neuropathy | Phase 2 / Phase 3 | Unknown | Mendel AI | 60 | 2021-02-15 | 2021-02-04 |
Cancer Pain (1) · Neoplasms (1) · Prostatic Neoplasms (1)
Memantine (1) · Venlafaxine Hydrochloride (1)
United States (2) · Egypt (1)